Skip to content

GSK

GSK Plc

NYSE · Healthcare · Drug Manufacturers - General · GB

$51.16
+5.05%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
—
EBIT
—
EPS
—
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
+5.7%
EBITDA
+44.9%
EPS
+77.2%

Three-year CAGR

Revenue
+3.7%
EBITDA
+6.5%
EBIT
+9.0%
Net income
-27.4%
EPS
-27.6%
Free cash flow
-4.8%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026